Nanomedicines for cardiovascular disease
Top Cited Papers
Open Access
- 3 April 2023
- journal article
- review article
- Published by Springer Nature in Nature Cardiovascular Research
- Vol. 2 (4) , 351-367
Abstract
The leading cause of death in the world, cardiovascular disease (CVD), remains a formidable condition for researchers, clinicians and patients alike. CVD comprises a broad collection of diseases spanning the heart, the vasculature and the blood that runs through and interconnects them. Limitations in CVD therapeutic and diagnostic landscapes have generated excitement for advances in nanomedicine, a field focused on improving patient outcomes through transformative therapies, imaging agents and ex vivo diagnostics. CVD nanomedicines are fundamentally shaped by their intended clinical application, including (1) cardiac or heart-related biomaterials, which can be functionally (for example, mechanically, immunologically, electrically) improved by incorporating nanomaterials; (2) the vasculature, involving systemically injected nanotherapeutics and imaging nanodiagnostics, nano-enabled biomaterials or tissue-nanoengineered solutions; and (3) improving the sensitivity and/or specificity of ex vivo diagnostic devices for patient samples. While immunotherapy has developed into a key pillar of oncology in the past dozen years, CVD immunotherapy and immunoimaging are recently emergent and likely to factor substantially in CVD management in the coming decade. The nanomaterials in CVD-related clinical trials and many promising preclinical strategies indicate that nanomedicine is on the cusp of greatly impacting patients with CVD. Here we review these recent advances, highlighting key clinical opportunities in the rapidly emerging field of CVD nanomedicine.Keywords
Funding Information
- American Heart Association (18TPA34230113)
- Office of Extramural Research (R01 CA244491)
This publication has 157 references indexed in Scilit:
- Delivery of Nox2-NADPH oxidase siRNA with polyketal nanoparticles for improving cardiac function following myocardial infarctionBiomaterials, 2013
- Atheroprotective communication between endothelial cells and smooth muscle cells through miRNAsNature Cell Biology, 2012
- In vivo prevention of arterial restenosis with paclitaxel-encapsulated targeted lipid–polymeric nanoparticlesProceedings of the National Academy of Sciences, 2011
- Multimodal Clinical Imaging To Longitudinally Assess a Nanomedical Anti-Inflammatory Treatment in Experimental AtherosclerosisMolecular Pharmaceutics, 2010
- Local arterial nanoparticle delivery of siRNA for NOX2 knockdown to prevent restenosis in an atherosclerotic rat modelGene Therapy, 2010
- Targeting stents with local delivery of paclitaxel-loaded magnetic nanoparticles using uniform fieldsProceedings of the National Academy of Sciences, 2010
- Multiplexed imaging of surface enhanced Raman scattering nanotags in living mice using noninvasive Raman spectroscopyProceedings of the National Academy of Sciences, 2009
- Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primatesProceedings of the National Academy of Sciences, 2008
- Localization to atherosclerotic plaque and biodistribution of biochemically derivatized superparamagnetic iron oxide nanoparticles (SPIONs) contrast particles for magnetic resonance imaging (MRI)Biomedical Microdevices, 2007
- Cardioprotective effects of cerium oxide nanoparticles in a transgenic murine model of cardiomyopathyCardiovascular Research, 2007